We are live on ! Find out more
AXSM icon

Axsome Therapeutics

176 hedge funds and large institutions have $1.51B invested in Axsome Therapeutics in 2021 Q2 according to their latest regulatory filings, with 24 funds opening new positions, 67 increasing their positions, 50 reducing their positions, and 31 closing their positions.

New
Increased
Maintained
Reduced
Closed

34% more repeat investments, than reductions

Existing positions increased: 67 | Existing positions reduced: 50

15% more capital invested

Capital invested by funds: $1.31B → $1.51B (+$200M)

0% more funds holding in top 10

Funds holding in top 10: 33 (0)

2.09% less ownership

Funds ownership: 61.62%59.54% (-2.1%)

4% less funds holding

Funds holding: 184176 (-8)

23% less first-time investments, than exits

New positions opened: 24 | Existing positions closed: 31

53% less call options, than puts

Call options by funds: $28.4M | Put options by funds: $60.4M

Holders
176
Holders Change
-8
Holders Change %
-4.35%
% of All Funds
3.06%
Holding in Top 10
3
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.05%
New
24
Increased
67
Reduced
50
Closed
31
Calls
$28.4M
Puts
$60.4M
Net Calls
-$32M
Net Calls Change
+$7.45M

AXSM Hedge Fund Activity: Q2 2021 in Review

176 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Axsome Therapeutics (AXSM) for Q2 2021, worth a combined $1.51B — up 15% from $1.31B a quarter earlier.

Sellers outnumbered buyers: 31 funds closed out of AXSM and 24 opened new positions — a net loss of 7 holders — while 50 trimmed existing stakes and 67 added.

The largest buyer was Perceptive Advisors, opening a new position worth an estimated $33.2M. The largest seller was AllianceBernstein, cutting an estimated $36M.

  • 176 institutional investors held Axsome Therapeutics (AXSM) as of Q2 2021, down from 184 in Q1 2021.
  • Funds reported $1.51B of Axsome Therapeutics stock for Q2 2021, up 15% quarter-over-quarter.
  • 24 funds opened new Axsome Therapeutics positions in Q2 2021 and 31 closed out, a net change of -7 holders.
  • The largest Axsome Therapeutics buyer in Q2 2021 was Perceptive Advisors, an estimated $33.2M added.
  • The largest Axsome Therapeutics seller in Q2 2021 was AllianceBernstein, an estimated $36M sold.

Based on aggregated 13F filings for Q2 2021.